Catabasis Pharmaceuticals Inc. (Nasdaq: CATB) entered a joint research collaboration with Sarepta Therapeutics (Nasdaq: SRPT) to explore a combination drug treatment approach for Duchenne muscular dystrophy. Shares of Catabasis Pharmaceuticals surged $1.77 to close at $6.25 while Sarepta Therapeutics stock dropped $1.26 to close at $60.98.
Catabasis Pharmaceuticals enters collaboration with Sarepta Therapeutics
September 29, 2016 at 17:37 PM EDT